Pharvaris NVNASDAQ:PHVS
- LAST PRICE17.4000
- TODAY'S CHANGE (%)-0.0400 (-0.2294%)
- Bid / Lots6.9600/ 2
- Ask / Lots27.8400/ 2
- Open / Previous Close17.6900 / 17.4400
- Day Range
- 52 Week Range
- Volume35,619
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PHVS |
|---|---|---|
| 09:32 ET | 201 | 18.125 |
| 10:30 ET | 200 | 17.35 |
| 10:32 ET | 200 | 17.19 |
| 10:33 ET | 100 | 17.38 |
| 11:13 ET | 411 | 17.2 |
| 11:15 ET | 112 | 17.155 |
| 11:26 ET | 100 | 17.34 |
| 12:16 ET | 10000 | 17.25 |
| 01:51 ET | 100 | 17.3 |
| 02:09 ET | 100 | 17.35 |
| 03:12 ET | 100 | 17.225 |
| 03:32 ET | 100 | 17.19 |
| 03:38 ET | 1800 | 17.225 |
| 03:52 ET | 9925 | 17.39 |
| 03:56 ET | 100 | 17.255 |
| 03:57 ET | 1400 | 17.36 |
| 03:59 ET | 585 | 17.4 |
Jul 3, 2024
DJ Pharvaris Is Maintained at Outperform by Oppenheimer, from 8:13AM ET on Wednesday Jul 03, 2024 by Dow Jones
8:13AM ET on Wednesday Jul 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pharvaris NV | 938.6M | -6.8x | --- |
Viridian Therapeutics Inc | 1.0B | -3.7x | --- |
Tyra Biosciences Inc | 1.1B | -11.9x | --- |
Humacyte Inc | 970.5M | -7.9x | --- |
Praxis Precision Medicines Inc | 984.4M | -3.6x | --- |
ARS Pharmaceuticals Inc | 1.1B | -21.1x | --- |
Company Information
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Contact Information
- Headquarters
- J.H. Oortweg 21LEIDEN, Netherlands 2333 CH
- Phone
- ---
- Fax
- ---
Executives
- Chief Executive Officer, Co-Founder, Executive Director
- Berndt Modig
- Co-Founder, Chief Operating Officer, Chief Scientific Officer
- Jochen Knolle
- Co-Founder, Non-Executive Director
- Hans Schikan
- Co-Founder, Chief Early Development Officer
- Anne Lesage
- Chief Financial Officer
- David Nassif
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $938.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 53.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -3.07 |
EPS | $-2.58 |
Book Value | $7.96 |
P/E Ratio | -6.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
